ACHIEVE LIFE SCIENCES, INC. Uncategorized Contracts & Agreements

52 Contracts & Agreements
Recent Contracts
Category
Company
Industry
Jur. Jurisdiction
Filed
Open Market Sale AgreementSM, dated September 27, 2024, between Achieve Life Sciences, Inc. and Jefferies LLC
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
NY
2024
Contingent Convertible Debt Agreement, dated July 25, 2024, between Achieve Life Sciences, Inc., and Silicon Valley Bank, a division of First-Citizens Bank & Trust Company
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
CA
2024
ACHIEVE LIFE SCIENCES, INC. 1040 West Georgia Street, Suite 1030 Vancouver, BC V6E 4H1
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
WA
2023
Letter of Variation, dated September 28, 2020, by and between Achieve Pharma UK Limited and Anthony Clarke
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2020
Letter of Variation, dated September 28, 2020, by and between Achieve Pharma UK Limited and Richard Stewart
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2020
Description of Securities Registered Under Section 12 of the Securities Exchange Act of 1934
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2020
Form of Leak-out Agreement
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2019
At The Market Offering Agreement, dated June 7, 2019, by and between Achieve Life Sciences, Inc. and H.C. Wainwright & Co., LLC
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
NY
2019
CONTINGENT VALUE RIGHTS AGREEMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
DE
2017
Lock-up Agreement
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2017
SUPPORT AGREEMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
DE
2017
SUPPORT AGREEMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
DE
2017
AGREEMENT BETWEEN ONCOGENEX TECHNOLOGIES, INC. (OGX) AND TEVA PHARMACEUTICAL INDUSTRIES LTD. (Teva)
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2015
EX-101 INSTANCE DOCUMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
CA
2011
EX-101 INSTANCE DOCUMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
DE
2011
/s/ Scott Cormack Scott Cormack, President & CEO
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2010
OncoGenex Pharmaceuticals, Inc.
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
NY
2010
a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer (CRPC), expected to initiate in the second quater of 2010...
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
NY
2010
a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer (CRPC), expected to initiate in the second quater of 2010...
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2010
a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer (CRPC), expected to initiate in the second quater of 2010...
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2010
a phase 3 clinical trial of OGX-011 in approximately 300 patients with second-line castrate resistant prostate cancer (CRPC), expected to initiate in the second quater of 2010...
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2010
OncoGenexTechnologies Inc. is a wholly owned subsidiary of OncoGenexPharmaceuticals, Inc. NASD- OGXI www.oncogenex.com
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2010
Consolidated Financial Statements
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
WA
2009
Consolidated Financial Statements
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2009
Consolidated Financial Statements
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2009
Agreement and Consent Form
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2009
longer survival duration when adding OGX-011 to first-line docetaxel compared to first-line docetaxel alone in patients with CRPC within a randomized phase 2 trial
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
NY
2009
SECOND AMENDING AGREEMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2008
SECOND AMENDING AGREEMENT AND CONSENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2008
SECOND AMENDMENT TO ARRANGEMENT AGREEMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2008
FIRST AMENDMENT TO ARRANGEMENT AGREEMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2008
THIRDAMENDMENT TO AMENDED AND RESTATED RIGHTS AGREEMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2008
SONUS PHARMACEUTICALS, INC. 1522 217th PL S.E., Suite 100 Bothell, Washington 98021 January 11, 2008
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2008
SonusPharmaceuticals, Inc. ExecutiveCompensation Program
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2006
SonusPharmaceuticals, Inc. CompensationPolicy
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2006
Amendedand Restated Sonus Pharmaceuticals, Inc. ExecutiveCompensation Program
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2005
EXHIBIT A FORM OF STOCKHOLDERS AGREEMENT
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
NY
2004
TOCOSOL Drug Delivery Technology
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2004
TOCOSOL Drug Delivery Technology
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2004
TOCOSOL Drug Delivery Technology
ACHIEVE LIFE SCIENCES, INC.
Biotechnology
2004